HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kevin Grogan

Managing Editor, Europe

Manchester, UK

Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.

Latest From Kevin Grogan

Bayer Cuts Dividend To The Bone To Cut Debt

The embattled German major is touting a promising mid-stage thrombolytic but the spotlight this week has continued to shine on its business model and high levels of debt.

Business Strategies Restructuring

Ambitious AAX Wants To Be Key Player In Next-Generation Antibodies

Emerging Company Profile: The Swedish biotech’s CEO Maria Lisa Knudsen believes that the firm’s two technologies make it an attractive prospective partner for big pharma. 

Sweden Emerging Company Profile

IsomAb Nabs Decent Seed Funding Despite Tricky Funding Climate

The University of Nottingham spin-out has raised £7.5m for a candidate that could halt the progression of peripheral arterial disease in diabetics.

Financing Cardiovascular

Almirall Adds Novo Nordisk Drug To Dermatology Pipeline

The Spanish drugmaker has licensed an IL-21 inhibitor which has been sitting on the shelf at Novo Nordisk and plans to start Phase II trials soon for as-yet undisclosed dermatological diseases.

Deals Sales & Earnings

Applied Therapeutics Takes Strong Swipe At SORD With Govorestat

Govorestat could soon be filed for a second indication after impressing as a potential treatment for SORD deficiency, one of the most common forms of recessive hereditary neuropathy for which there are no approved therapies.

Rare Diseases Clinical Trials

Genmab On The Hunt For Late-Stage Assets

The Danish biotech has dipped its toe into co-commercialization recently and is seeking more candidates that are getting closer to the market.

Sales & Earnings M & A
See All
UsernamePublicRestriction

Register